FOXM1 and neoplasm: Through our own work, we were able to demonstrate that in vivo inhibition of FOXM1 by siRNA FOXM1 injections can suppress tumor growth in TNBC tumor xenograft models in mice [62], suggesting that FOXM1 is a clinically significant molecular target driving the TNBC tumorigenesis.